Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

Shares of Biohaven (NYSE:BHVN) fell ~11% in the premarket on Thursday after the company said that the FDA has extended the ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

BHVN's Troriluzole awaits pivotal FDA approval in 2025, backed by $600M funding. Explore its diverse pipeline and promising ...

Biohaven Ltd. is the company that remained after the original Biohaven sold its migraine therapeutic assets to pharmaceutical giant Pfizer Inc. in 2022 in a deal valued at $13 billion.

Biohaven's share price jumped about 10% on Monday in the wake of the deal. Welcome to new (Bio) Haven: CEO hopes to strike gold twice with remaining R&D crew after Pfizer deal It's been something ...